With the recent FDA approvals of new immunotherapies to treat different types of cancer, it is becoming evident that combination treatments—the use of two or more therapies—is more effective than treating it with one therapy alone. Unlocking the immune system’s full potential to eliminate the disease requires knowing the right combination to that lock, whether with multiple immunotherapy drugs, or with other treatments like chemotherapy, radiation, or focused ultrasound, an early-stage, non-invasive therapeutic technology.
Focused ultrasound may play a role in improving the effectiveness of immunotherapy to fight cancer. On Tuesday, January 17, 2017, the Focused Ultrasound Foundation (FUS) will host “Immunotherapy: Revolutionizing Cancer Treatment," a 90-minute webinar featuring Jill O’Donnell-Tormey, Ph.D., CEO and director of scientific affairs at the Cancer Research Institute. Dr. O’Donnell-Tormey will present an introduction to the organization, its focus on combination therapies to maximize treatment efficacy, and important recent developments in cancer immunotherapy research.
Immunotherapy: Revolutionizing Cancer Treatment
Tuesday, January 17, 2017
11:00 a.m. – 12:30 p.m. ET
Jill O’Donnell-Tormey, Ph.D.
CEO and Director of Scientific Affairs
Cancer Research Institute